Literature DB >> 8579641

[Ca2+]i in human heart failure: a review and discussion of current areas of controversy.

R Liao1, P A Helm, R J Hajjar, C Saha, J K Gwathmey.   

Abstract

Multiple abnormalities have been reported in the setting of human heart failure. It is unclear whether detected changes reflect adaptive alterations in myocardium subjected to increased and sustained hemodynamic overload or are pathogenic to the disease process. As a result of the observation that the primary defect in heart failure is decreased pump function, investigators have concentrated their efforts on determining systolic [Ca2+]i as a logical corollary and a causative mechanism for contractile dysfunction. A simple cause and effect relationship has therefore been proposed with regard to contractile dysfunction and [Ca2+]i. Yet some investigators have found no difference in peak systolic [Ca2+]i between failing and non-failing human myocardium, whereas others have found peak [Ca2+]i to be significantly reduced in failing hearts. Resting calcium concentrations have been reported either to be elevated in failing human myocardium or not different from non-failing human myocardium. Investigators should now appreciate that the force-calcium relationship is not a simple relationship. One must take into account the prolonged time course and slowed mobilization of [Ca2+]i as opposed to simply peak [Ca2+]i. When put in perspective of mechanisms and determinants of the Ca(2+)-force relationship, we begin to realize that failing human myocardium has the "potential" to generate normal levels of force. Only when stressed by [Ca2+]i overload and/or frequency perturbation does myocardium from patients with end-stage heart disease demonstrate contractile failure. Although [Ca2+]i availability and mobilization are likely to play a role in the systolic as well as diastolic dysfunction reported in human heart failure, it is likely that other mechanisms are involved as well (e.g., myocardial energetics). Myocardial energetics is directly related to [Ca2+]i and mobilization in failing human myocardium, because metabolites, e.g., ADP, inhibit pumps, such as sarcoplasmic reticulum Ca2+ ATPase activity. We therefore conclude that there is a role for intracellular calcium mobilization and myocardial energetics for systolic and diastolic dysfunction seen in human heart failure.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8579641      PMCID: PMC2588906     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  39 in total

1.  Changes in myofibrillar content and Mg-ATPase activity in ventricular tissues from patients with heart failure caused by coronary artery disease, cardiomyopathy, or mitral valve insufficiency.

Authors:  E D Pagani; A A Alousi; A M Grant; T M Older; S W Dziuban; P D Allen
Journal:  Circ Res       Date:  1988-08       Impact factor: 17.367

2.  Differential effect of DPI 201-106 on the sensitivity of the myofilaments to Ca2+ in intact and skinned trabeculae from control and myopathic human hearts.

Authors:  R J Hajjar; J K Gwathmey; G M Briggs; J P Morgan
Journal:  J Clin Invest       Date:  1988-11       Impact factor: 14.808

Review 3.  Sarcoplasmic reticulum gene expression in cardiac hypertrophy and heart failure.

Authors:  M Arai; H Matsui; M Periasamy
Journal:  Circ Res       Date:  1994-04       Impact factor: 17.367

4.  Calcium channel binding characteristics in the human heart.

Authors:  M S Finkel; R E Patterson; W C Roberts; T D Smith; H R Keiser
Journal:  Am J Cardiol       Date:  1988-12-01       Impact factor: 2.778

5.  Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol.

Authors:  F Waagstein; K Caidahl; I Wallentin; C H Bergh; A Hjalmarson
Journal:  Circulation       Date:  1989-09       Impact factor: 29.690

6.  Ca2+ uptake by cardiac sarcoplasmic reticulum from patients with idiopathic dilated cardiomyopathy.

Authors:  M A Movsesian; M R Bristow; J Krall
Journal:  Circ Res       Date:  1989-10       Impact factor: 17.367

7.  Inotropic response to DPI 201-106 in the failing human heart.

Authors:  M Böhm; F Diet; B Kemkes; M Wankerl; E Erdmann
Journal:  Br J Pharmacol       Date:  1989-09       Impact factor: 8.739

8.  Intracellular calcium transient of working human myocardium of seven patients transplanted for congestive heart failure.

Authors:  C F Vahl; A Bonz; T Timek; S Hagl
Journal:  Circ Res       Date:  1994-05       Impact factor: 17.367

9.  Contractile properties and Ca2+ release activity of the sarcoplasmic reticulum in dilated cardiomyopathy.

Authors:  A D'Agnolo; G B Luciani; A Mazzucco; V Gallucci; G Salviati
Journal:  Circulation       Date:  1992-02       Impact factor: 29.690

10.  Energetics of isometric force development in control and volume-overload human myocardium. Comparison with animal species.

Authors:  G Hasenfuss; L A Mulieri; E M Blanchard; C Holubarsch; B J Leavitt; F Ittleman; N R Alpert
Journal:  Circ Res       Date:  1991-03       Impact factor: 17.367

View more
  4 in total

1.  Parvalbumin gene transfer corrects diastolic dysfunction in diseased cardiac myocytes.

Authors:  P A Wahr; D E Michele; J M Metzger
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

2.  In vitro studies of early cardiac remodeling: impact on contraction and calcium handling.

Authors:  Kaylan M Haizlip; Paul M L Janssen
Journal:  Front Biosci (Schol Ed)       Date:  2011-06-01

Review 3.  Linking Biochemical and Structural States of SERCA: Achievements, Challenges, and New Opportunities.

Authors:  Rodrigo Aguayo-Ortiz; L Michel Espinoza-Fonseca
Journal:  Int J Mol Sci       Date:  2020-06-10       Impact factor: 5.923

Review 4.  Calcium and Heart Failure: How Did We Get Here and Where Are We Going?

Authors:  Natthaphat Siri-Angkul; Behzad Dadfar; Riya Jaleel; Jazna Naushad; Jaseela Parambathazhath; Angelia A Doye; Lai-Hua Xie; Judith K Gwathmey
Journal:  Int J Mol Sci       Date:  2021-07-09       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.